Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.

"CONFLICT OF INTEREST Stefan Zeuzem consults for and is on the speakers' bureau for Gilead and BioMarin. He consults for NovoNordisk and GSK. Jonel Trebicka has received speaking and/or consulting fees from Versantis, Gore, Boehringer‐Ingelheim, Alexion, Falk, Mallinckrodt, Grifols and CSL Behring."

"FUNDING INFORMATION Jonel Trebicka is supported by the German Research Foundation project ID 403224013–SFB 1382 (A09); by the German Federal Ministry of Education and Research (BMBF) for the DEEP‐HCC project; by the Hessian Ministry of Higher Education, Research, and the Arts (HMWK) for the ENABLE cluster project; and by Eurostars (Grant ID 12350). The MICROB‐PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects have received funding from the European Union's Horizon 2020 research and innovation program. The manuscript reflects only the authors' views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding information Bundesministerium für Bildung und Forschung, Grant/Award Number: DEEP-HCC; Deutsche Forschungsgemeinschaft, Grant/Award Number: 403224013 -SFB 1382 (A09); Eurostars, Grant/Award Number: 12350; H2020 European Research Council, Grant/Award Number: 668031, 731875, 825694, 847949 and 964590; Hessian Ministry of Higher Education, Research and the Arts (HMWK)"